LAB150 Innovation Award awarded to UHN's Brian Wu at Krembil Research Day
LAB150 is a drug development collaboration between MaRS Innovation and a German-based CRO, Evotec SE, developed to accelerate Toronto’s academic research into market-ready products. With a combined multi-million-dollar financial commitment by MaRS Innovation and Evotec SE, this recently formed partnership aims to accelerate the development and commercialization of therapeutically focused programs and technologies with award amounts up to 400k USD.
LAB150 likes to recognize the community’s outstanding researchers committed to translating their academic research into novel therapeutic approaches that will ultimately improve patient care. As such, LAB150 was pleased to sponsor the “LAB150 Innovation Award” for UHN's Krembil Research Day. This award was presented to Krembil's Brian Wu for his work on Ephrin B2 Signaling in the Development of Pulmonary Fibrosis, who was the top-scoring oral presenter (both 3-minute and 10-minute oral presentations) as evaluated by LAB150 representatives. Criteria for this award included the likelihood for the research to be translated into the clinic, how innovative the research was, if the research was focused on a disease/indication of high unmet medical need, and presentation style.
Congratulations to Brian!